Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Andrea Botticelli(Policlinico Umberto I), Paolo Marchetti(Istituto Dermopatico dell'Immacolata)
Journal of Translational Medicine
August 6, 2018
10.1186/s12967-018-1595-3
Cited by 129

Related Papers

Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients
|Journal of Personalized Medicine|2020|44
Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
|Clinical Cancer Research|2022|30
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells
|EBioMedicine|2020|17
Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy
|Cancers|2020|14
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, <i>ERBB2</i>–Negative Metastatic Breast Cancer
|JAMA Network Open|2025|11